Skip to Main Content (Press Enter)

Logo UNIME
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Competenze

Competenze e Professionalità
Logo UNIME

|

UNIFIND - Competenze e Professionalità

unime.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Competenze
  1. Pubblicazioni

Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients

Articolo
Data di Pubblicazione:
2022
Abstract:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective and safe lipid-lowering treatments (LLT). The primary endpoint of the study was to assess the prevalence of patients eligible for treatment with PCSK9 inhibitors in a real-life clinical setting in Italy before and after the recent enlargement of reimbursement criteria. For this study, we consecutively considered the clinical record forms of 6231 outpatients consecutively admitted at the Lipid Clinic of the University Hospital of Bologna (Italy). Patients were stratified according to whether they were allowed or not allowed to access to treatment with PCSK9 inhibitors based on national prescription criteria and reimbursement rules issued by the Italian Medicines Agency (AIFA). According to the indications of the European Medicines Agency (EMA), 986 patients were candidates to treatment with PCSK9 inhibitors. However, following the prescription criteria issued by AIFA, only 180 patients were allowed to access to PCSK9 inhibitors before reimbursement criteria enlargement while 322 (+14.4%) with the current ones. Based on our observations, low-cost tailored therapeutic interventions for individual patients can significantly reduce the number of patients potentially needing treatment with PCSK9 inhibitors among those who are not allowed to access to the treatment. The application of enlarged reimbursement criteria for PCSK9 inhibitors could mildly improve possibility to adequately manage high-risk hypercholesterolemic subjects in the setting of an outpatient lipid clinic.
Tipologia CRIS:
14.a.1 Articolo su rivista
Keywords:
cardiovascular risk; hypercholesterolemia; LDL-C; LDL-C goal; PCSK9 inhibitors; tailored medicine
Elenco autori:
Fogacci, F.; Giovannini, M.; Grandi, E.; Imbalzano, E.; Degli Esposti, D.; Borghi, C.; Cicero, A. F. G.
Autori di Ateneo:
IMBALZANO Egidio
Link alla scheda completa:
https://iris.unime.it/handle/11570/3247588
Pubblicato in:
JOURNAL OF CLINICAL MEDICINE
Journal
  • Informazioni
  • Assistenza
  • Accessibilità
  • Privacy
  • Utilizzo dei cookie
  • Note legali

Realizzato con VIVO | Designed by Cineca | 25.11.4.0